Mindfulness vs CBT: A critical review for anxiety and depression

Introduction

Mindfulness is the awareness that arises from intentionally attending to the present moment without judgment (Kabat-Zinn, 2013). Its integration into clinical practice underpins Mindfulness-Based Interventions (MBIs), such as Mindfulness-Based Stress Reduction (MBSR), originally developed for emotional distress from physical illness (Kabat-Zinn et al., 1985). Mindfulness-Based Cognitive Therapy (MBCT) was designed to prevent depressive relapse by combining mindfulness with Cognitive Behavioural Therapy (CBT) (Segal et al., 2002). While CBT focuses on identifying and modifying maladaptive thoughts and behaviours (Beck, 2011), MBCT emphasises non-reactive awareness of thoughts (Segal et al., 2002). CBT remains the first-line treatment for depression and anxiety recommended by the National Institute for Health and Care Excellence (NICE). Despite CBT’s strong evidence base, access is constrained by cost and therapist availability, creating a treatment gap (Kazdin, 2017), highlighting the need for alternatives (Cuijpers et al., 2019). While group MBCT is endorsed for relapse prevention and mindfulness for less severe depression, MBIs are not recommended for severe depression or anxiety and are discouraged for social anxiety (NICE, 2011, 2013, 2022b). This essay critically evaluates whether MBIs should be offered as an alternative to CBT as a first-line treatment for depression and anxiety in adulthood.

Depression: equivalent for some, not for others

Depression is multidimensional, with patient presentations varying in severity, course, and clinical subtype (American Psychiatric Association, 2022). Although MBIs appear broadly comparable to CBT in reducing depressive symptoms and relapse, supporting their consideration as a first-line alternative (Drüge et al., 2024), recommendations are context-dependent. A recent meta-analysis using indirect comparisons reported similar effects for MBIs (Mean Difference (MD) ≈ −4.9) and CBT (MD ≈ −4.6) relative to Treatment-As-Usual (TAU) (Buschner et al., 2025). However, the high heterogeneity (I² = 72.7%) indicates substantial variability between studies, undermining the transitivity assumption and limiting confidence in the validity of the indirect comparison. A direct head-to-head meta-analysis found MBIs and CBT to be equivalent at post-treatment (Hedges g = −0.009) and 12-month follow-up (g = −0.033), supporting equal efficacy (Sverre et al., 2023). However, this equivalence only held for mild-to-moderate depression, not severe cases. While the large, comorbid sample (N = 2705) enhances generalisability, it masks disorder-specific conclusions. A large body of evidence, including robust individual Randomised Control Trials (RCTs) for mild–moderate depression, supports equivalent efficacy (Strauss et al., 2023), though some lack longer follow-ups, limiting conclusions about durability (Abolghasemi et al., 2015; Omidi et al., 2013). In more severe and chronic cases, evidence is sparse and mixed. MBIs showed no advantage over TAU, while CBT showed superiority, supported by strong external validity from an RCT conducted via multi-site delivery (Michalak et al., 2015). Conversely, in recurrent depression, mindfulness was identified as the key active ingredient in reducing relapse risk in a dismantling trial, highlighting a potentially distinct role for MBCT within treatment pathways (Williams et al., 2014). A meta-analysis reported that MBCT provided stronger short-term relapse prevention, whereas CBT showed longer-term effects, albeit less consistent (Zhou et al., 2023). Given relapse risk is highest within the first year (Guidi et al., 2016), MBCT’s short-term preventative profile may be particularly suitable during this period of highest clinical risk. A 24-month RCT reported numerically similar relapse rates between MBCT and CBT (44% vs. 52%), though as the trial was not powered as a non-inferiority design, this descriptive similarity should not be interpreted as established equivalence (Farb et al., 2018). Severity, chronicity, and clinical subtype may moderate the comparative efficacy of MBIs and CBT. Recommendations for MBIs as an alternative to CBT should be specific to mild-moderate and recurrent depression, aligned with NICE (2022b), though uncertainty remains about their real-world effectiveness, which requires consideration of pragmatic trials.

Mindfulness: a scalable alternative for overstretched services

Beyond efficacy, MBIs can be offered as an effective, scalable, low-intensity first-line option for depression within the National Health Service (NHS). While NICE recommends group MBCT (NICE, 2022b), this may limit accessibility for those with irregular schedules, such as shift workers and carers. The LIGHTMind RCT, conducted in a real-world public health setting, compared supported MBCT self-help with supported CBT self-help — both formats involving brief practitioner contact rather than full therapist-led sessions — and found MBCT superior at 16 weeks and equivalent at 42 weeks, with lower overall practitioner input, supporting clinical effectiveness (Strauss et al., 2023). Complementing this, internet-delivered MBIs produced comparable transdiagnostic outcomes to iCBT, with over 60% no longer meeting diagnostic criteria at follow-up (Kladnitski et al., 2020). However, both trials reported high dropout rates, limiting confidence in sustained engagement (Kladnitski et al., 2020; Strauss et al., 2023). Nevertheless, the findings are clinically significant in the context of NHS services, where demand exceeds therapist availability and waiting times frequently exceed recommended thresholds (Punton et al., 2022). Both trials used geographically and sociodemographically diverse samples with comorbid depression and anxiety, enhancing generalisability (Kladnitski et al., 2020; Strauss et al., 2023); however, they do not permit conclusions about anxiety alone, which warrants separate evaluation. The convergent evidence from these trials supports MBIs as a scalable and clinically effective alternative to CBT for some cases of depression.

Anxiety: promising for GAD, but the evidence is thin

For anxiety, MBIs show promise as a first-line treatment alternative to CBT. However, disorder-specific evidence remains limited and mixed, creating uncertainty about their clinical viability (Haller et al., 2021). A meta-analysis reported no significant differences between MBIs and CBT at post-treatment (SMD = −0.01) or follow-up (SMD = 0.05), suggesting comparable efficacy (Li et al., 2021). Given MBIs were favoured in subclinical anxiety (SMD = −0.36), they may have inflated overall effects and limited applicability to clinical populations, as CBT remained more efficacious for severe presentations (Koszycki et al., 2007). Anxiety disorders are heterogeneous (Ohi et al., 2025), yet meta-analyses aggregated across diagnoses, potentially obscuring disorder-specific effects (Li et al., 2021). Although earlier evidence suggests comparable outcomes across mixed anxiety samples (Arch et al., 2013), disorder-specific comparisons remain sparse. For Generalised Anxiety Disorder (GAD), a noninferiority RCT found MBCT comparable to CBT at post-treatment and 3-month follow-up (Jiang et al., 2022). However, noninferiority designs do not establish equivalence, and the conclusion depended on a subjective 10% margin (Ofori et al., 2023). Short follow-up durations also limit understanding of how treatments compare over longer periods and may underestimate MBI treatment effects (Miller et al., 1995). Overall, MBCT may represent a credible alternative for GAD, but more comparative, longitudinal evidence is required before it can be recommended as a first-line treatment to CBT.

Social anxiety: where NICE may need to catch up

For Social Anxiety Disorder (SAD), a broader body of comparative evidence exists, with mixed findings. Earlier meta-analyses favoured CBT for treatment efficacy (Mayo-Wilson et al., 2014; Norton et al., 2015) and more recent evidence further supported this (Liu et al., 2021). However, the largest trial (N=137) included within Liu et al. (2021) found comparable reductions in symptom severity between group-delivered MBIs and CBT, maintained at 3-month follow-up (Kocovski et al., 2013). High attrition (~40%), above typical psychotherapy rates (Swift & Greenberg, 2012), may weaken confidence in these findings despite similar dropout across groups, suggesting comparable acceptability. A more recent RCT reported large and equivalent effects for MBSR (d = 1.79) and CBT (d = 1.74), maintained at 12-month follow-up (Goldin et al., 2016), suggesting MBIs may match CBT in efficacy. Both studies reported that MBIs and CBT target shared mechanisms of change: attentional control, reappraisal, and avoidance, though conclusions are limited by reliance on subjective self-report measures (Goldin et al., 2016; Kocovski et al., 2013). Extending this, a functional magnetic resonance imaging (fMRI) RCT found no neural differences between CBT and MBIs, with both engaging similar brain networks and enhancing reappraisal and acceptance (Goldin et al., 2021), providing objective support for equivalence. More recent evidence suggests CBT and MBIs yield comparable outcomes, possibly via shared mechanisms, though more rigorous clinical and cost-effectiveness trials are needed to support MBIs as an alternative for SAD.

Beyond efficacy: preference, acceptability, and cost

While efficacy is central to evaluating MBIs as a first-line alternative to CBT, acceptability, preference, and cost-effectiveness are equally critical to real-world implementation (Hofmann et al., 2010). Evidence suggests comparable acceptability, with similar attrition rates across anxiety and depression trials (Li et al., 2021; Sverre et al., 2023). However, patient preferences may diverge: an RCT reported twice as many SAD participants preferred MBIs over CBT, yet preference did not influence clinical outcomes (Koszycki et al., 2022). Preference may nonetheless enhance satisfaction and adherence over time (Eigenhuis et al., 2024), supporting offering treatment choice. Economic comparisons are mixed. For depression, MBIs may reduce costs through lower practitioner contact time (Strauss et al., 2023), yet CBT produced marginally greater health gains at a modest additional cost, yielding an Incremental Cost-Effectiveness Ratio (ICER) of £11,366 per Quality-Adjusted Life Year (QALY) (Abu-Ashour et al., 2026), below accepted thresholds (NICE, 2022a), indicating CBT remains slightly more cost-effective. For anxiety, cost comparisons with CBT are limited by mixed samples and non-equivalent control conditions (Saha et al., 2020), constraining implementation conclusions.

Conclusion: Should the NHS offer it as a first-line alternative?

Overall, the evidence does not support MBIs as a universal first-line alternative to CBT for depression and anxiety; the question warrants disorder-specific consideration. For recurrent and mild-to-moderate depression, the evidence for clinical equivalence is reasonably robust (Sverre et al., 2023), with supportive though not definitive evidence for longer-term equivalence (Farb et al., 2018), and MBIs may offer advantages in scalability, cost, and accessibility within overstretched NHS services (Strauss et al., 2023). The heterogeneous nature of anxiety requires disorder-subtype consideration. For GAD, the evidence remains underdeveloped to confidently offer MBIs as an alternative to CBT, aligned with NICE (2011). For SAD, NICE’s current position discouraging mindfulness (NICE, 2013) may warrant reconsideration in light of more recent evidence, including neuroimaging data suggesting equivalence (Goldin et al., 2021). Evidence on underlying mechanisms supports MBIs as an alternative for some presentations, consistent with more personalised treatment (Parmentier et al., 2019). Future research should prioritise disorder-specific, longitudinal, and pragmatic trials — including adequately powered non-inferiority and equivalence designs - to clarify whether MBIs are equivalent or superior for anxiety and other depression subtypes. Current evidence supports MBIs as an alternative to CBT for mild-to-moderate and recurrent depression, but the case for anxiety remains unproven and should not yet justify a change to first-line recommendations.

Thank you very much for reading - if you got this far!

Sophia

References

Abolghasemi, A., Gholami, H., Narimani, M., & Gamji, M. (2015). The Effect of Beck’s Cognitive Therapy and Mindfulness-Based Cognitive Therapy on Sociotropic and Autonomous Personality Styles in Patients With Depression. Iranian Journal of Psychiatry and Behavioral Sciences, 9(4), e3665. https://doi.org/10.17795/ijpbs-3665

Abu-Ashour, W., Audas, R., Gamble, J.-M., Hawboldt, J., & Sale, J. E. M. (2026). A cost-utility analysis of mindfulness-based cognitive therapy versus cognitive behavioral therapy for major depressive disorder relapse prevention in primary care. Psychiatry Research, 358, 116996. https://doi.org/10.1016/j.psychres.2026.116996

American Psychiatric Association (Ed.). (2022). Diagnostic and statistical manual of mental disorders: DSM-5-TR (Fifth edition, text revision). American Psychiatric Association Publishing.

Arch, J. J., Ayers, C. R., Baker, A., Almklov, E., Dean, D. J., & Craske, M. G. (2013). Randomized clinical trial of adapted mindfulness-based stress reduction versus group cognitive behavioral therapy for heterogeneous anxiety disorders. Behaviour Research and Therapy, 51(4–5), 185–196. https://doi.org/10.1016/j.brat.2013.01.003

Beck, J. S. (2011). Cognitive behavior therapy: Basics and beyond (2nd ed). Guilford Press.

Buschner, A., Makiol, C., Huang, J., Mauche, N., & Strauß, M. (2025). Comparison of cognitive behavioral therapy and third-wave-mindfulness-based therapies for patients suffering from depression measured using the Beck-Depression-Inventory (BDI): A systematic literature review and network-meta-analysis. Journal of Affective Disorders, 379, 88–99. https://doi.org/10.1016/j.jad.2025.02.104

Cuijpers, P., Noma, H., Karyotaki, E., Cipriani, A., & Furukawa, T. A. (2019). Effectiveness and Acceptability of Cognitive Behavior Therapy Delivery Formats in Adults With Depression: A Network Meta-analysis. JAMA Psychiatry, 76(7), 700–707. https://doi.org/10.1001/jamapsychiatry.2019.0268

Drüge, M., Guthardt, L., Haller, E., Michalak, J., & Apolinário-Hagen, J. (2024). Cognitive Behavioral Therapy and Mindfulness-Based Cognitive Therapy for Depressive Disorders: Enhancing Access and Tailoring Interventions in Diverse Settings. Advances in Experimental Medicine and Biology, 1456, 199–226. https://doi.org/10.1007/978-981-97-4402-2_11

Eigenhuis, E., van Buuren, V. E. M., Boeschoten, R. E., Muntingh, A. D. T., Batelaan, N. M., & van Oppen, P. (2024). The Effects of Patient Preference on Clinical Outcome, Satisfaction and Adherence Within the Treatment of Anxiety and Depression: A Meta-Analysis. Clinical Psychology & Psychotherapy, 31(3), e2985. https://doi.org/10.1002/cpp.2985

Farb, N., Anderson, A., Ravindran, A., Hawley, L., Irving, J., Mancuso, E., Gulamani, T., Williams, G., Ferguson, A., & Segal, Z. V. (2018). Prevention of relapse/recurrence in major depressive disorder with either mindfulness-based cognitive therapy or cognitive therapy. Journal of Consulting and Clinical Psychology, 86(2), 200–204. https://doi.org/10.1037/ccp0000266

Goldin, P., A, M., H, J., F, B., R, H., & Jj, G. (2016). Group CBT versus MBSR for social anxiety disorder: A randomized controlled trial. Journal of Consulting and Clinical Psychology, 84(5). https://doi.org/10.1037/ccp0000092

Goldin, P. R., Thurston, M., Allende, S., Moodie, C., Dixon, M. L., Heimberg, R. G., & Gross, J. J. (2021). Evaluation of Cognitive Behavioral Therapy vs Mindfulness Meditation in Brain Changes During Reappraisal and Acceptance Among Patients With Social Anxiety Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(10), 1134–1142. https://doi.org/10.1001/jamapsychiatry.2021.1862

Guidi, J., Tomba, E., & Fava, G. A. (2016). The Sequential Integration of Pharmacotherapy and Psychotherapy in the Treatment of Major Depressive Disorder: A Meta-Analysis of the Sequential Model and a Critical Review of the Literature. The American Journal of Psychiatry, 173(2), 128–137. https://doi.org/10.1176/appi.ajp.2015.15040476

Haller, H., Breilmann, P., Schröter, M., Dobos, G., & Cramer, H. (2021). A systematic review and meta-analysis of acceptance- and mindfulness-based interventions for DSM-5 anxiety disorders. Scientific Reports, 11(1), 20385. https://doi.org/10.1038/s41598-021-99882-w

Hofmann, S. G., Sawyer, A. T., Witt, A. A., & Oh, D. (2010). The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. Journal of Consulting and Clinical Psychology, 78(2), 169–183. https://doi.org/10.1037/a0018555

Jiang, S.-S., Liu, X.-H., Han, N., Zhang, H.-J., Xie, W.-X., Xie, Z.-J., Lu, X.-Y., Zhou, X.-Z., Zhao, Y.-Q., Duan, A.-D., Zhao, S.-Q., Zhang, Z.-C., & Huang, X.-B. (2022). Effects of group mindfulness-based cognitive therapy and group cognitive behavioural therapy on symptomatic generalized anxiety disorder: A randomized controlled noninferiority trial. BMC Psychiatry, 22(1), 481. https://doi.org/10.1186/s12888-022-04127-3

Kabat-Zinn, J. (with Hanh, T. N.). (2013). Full Catastrophe Living (Revised Edition): Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness. Random House Publishing Group.

Kabat-Zinn, J., Lipworth, L., & Burney, R. (1985). The clinical use of mindfulness meditation for the self-regulation of chronic pain. Journal of Behavioral Medicine, 8(2), 163–190. https://doi.org/10.1007/BF00845519

Kazdin, A. E. (2017). Addressing the treatment gap: A key challenge for extending evidence-based psychosocial interventions. Behaviour Research and Therapy, 88, 7–18. https://doi.org/10.1016/j.brat.2016.06.004

Kladnitski, N., Smith, J., Uppal, S., James, M. A., Allen, A. R., Andrews, G., & Newby, J. M. (2020). Transdiagnostic internet-delivered CBT and mindfulness-based treatment for depression and anxiety: A randomised controlled trial. Internet Interventions, 20. https://doi.org/10.1016/j.invent.2020.100310

Kocovski, N. L., Fleming, J. E., Hawley, L. L., Huta, V., & Antony, M. M. (2013). Mindfulness and acceptance-based group therapy versus traditional cognitive behavioral group therapy for social anxiety disorder: A randomized controlled trial. Behaviour Research and Therapy, 51(12), 889–898. https://doi.org/10.1016/j.brat.2013.10.007

Koszycki, D., Benger, M., Shlik, J., & Bradwejn, J. (2007). Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behaviour Research and Therapy, 45(10), 2518–2526. https://doi.org/10.1016/j.brat.2007.04.011

Koszycki, D., Ilton, J., Dowell, A., & Bradwejn, J. (2022). Does treatment preference affect outcome in a randomized trial of a mindfulness intervention versus cognitive behaviour therapy for social anxiety disorder? Clinical Psychology & Psychotherapy, 29(2), 652–663. https://doi.org/10.1002/cpp.2658

Li, J., Cai, Z., Li, X., Du, R., Shi, Z., Hua, Q., Zhang, M., Zhu, C., Zhang, L., & Zhan, X. (2021). Mindfulness-based therapy versus cognitive behavioral therapy for people with anxiety symptoms: A systematic review and meta-analysis of random controlled trials. Annals of Palliative Medicine, 10(7), 7596–7612. https://doi.org/10.21037/apm-21-1212

Liu, X., Yi, P., Ma, L., Liu, W., Deng, W., Yang, X., Liang, M., Luo, J., Li, N., & Li, X. (2021). Mindfulness-based interventions for social anxiety disorder: A systematic review and meta-analysis. Psychiatry Research, 300, 113935. https://doi.org/10.1016/j.psychres.2021.113935

Mayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014). Psychological and pharmacological interventions for social anxiety disorder in adults: A systematic review and network meta-analysis. The Lancet. Psychiatry, 1(5), 368–376. https://doi.org/10.1016/S2215-0366(14)70329-3

Michalak, J., Schultze, M., Heidenreich, T., & Schramm, E. (2015). A randomized controlled trial on the efficacy of mindfulness-based cognitive therapy and a group version of cognitive behavioral analysis system of psychotherapy for chronically depressed patients. Journal of Consulting and Clinical Psychology, 83(5), 951–963. https://doi.org/10.1037/ccp0000042

Miller, J. J., Fletcher, K., & Kabat-Zinn, J. (1995). Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. General Hospital Psychiatry, 17(3), 192–200. https://doi.org/10.1016/0163-8343(95)00025-m

NICE. (2011, January 26). Generalised anxiety disorder and panic disorder in adults: Management [CG113]. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/cg113/chapter/Recommendations

NICE. (2013, May 22). Social anxiety disorder: Recognition, assessment and treatment [CG159]. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/cg159/chapter/Recommendations#interventions-that-are-not-recommended-to-treat-social-anxiety-disorder

NICE. (2022a, January 31). Economic evaluation | NICE technology appraisal and highly specialised technologies guidance: The manual | Guidance PMG36 | NICE. NICE. https://www.nice.org.uk/process/pmg36/chapter/economic-evaluation-2

NICE. (2022b, June 29). Depression in adults: Treatment and management [NG222]. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng222/chapter/Recommendations#treatment-resistant-depression

Norton, A. R., Abbott, M. J., Norberg, M. M., & Hunt, C. (2015). A systematic review of mindfulness and acceptance-based treatments for social anxiety disorder. Journal of Clinical Psychology, 71(4), 283–301. https://doi.org/10.1002/jclp.22144

Ofori, S., Tornberg, S. V., Kilpeläinen, T. P., Tikkinen, K. A. O., Guyatt, G. H., & Witte, L. P. W. (2023). Pros and Cons of Noninferiority Trials. European Urology Focus, 9(5), 711–714. https://doi.org/10.1016/j.euf.2023.10.003

Ohi, K., Fujikane, D., Takai, K., Kuramitsu, A., Muto, Y., Sugiyama, S., & Shioiri, T. (2025). Clinical features and genetic mechanisms of anxiety, fear, and avoidance: A comprehensive review of five anxiety disorders. Molecular Psychiatry, 30(10), 4928–4936. https://doi.org/10.1038/s41380-025-03155-1

Omidi, A., Mohammadkhani, P., Mohammadi, A., & Zargar, F. (2013). Comparing mindfulness based cognitive therapy and traditional cognitive behavior therapy with treatments as usual on reduction of major depressive disorder symptoms. Iranian Red Crescent Medical Journal, 15(2), 142–146. https://doi.org/10.5812/ircmj.8018

Parmentier, F. B. R., García-Toro, M., García-Campayo, J., Yañez, A. M., Andrés, P., & Gili, M. (2019). Mindfulness and Symptoms of Depression and Anxiety in the General Population: The Mediating Roles of Worry, Rumination, Reappraisal and Suppression. Frontiers in Psychology, 10, 506. https://doi.org/10.3389/fpsyg.2019.00506

Punton, G., Dodd, A. L., & McNeill, A. (2022). ‘You’re on the waiting list’: An interpretive phenomenological analysis of young adults’ experiences of waiting lists within mental health services in the UK. PloS One, 17(3), e0265542. https://doi.org/10.1371/journal.pone.0265542

Saha, S., Jarl, J., Gerdtham, U.-G., Sundquist, K., & Sundquist, J. (2020). Economic evaluation of mindfulness group therapy for patients with depression, anxiety, stress and adjustment disorders compared with treatment as usual. The British Journal of Psychiatry: The Journal of Mental Science, 216(4), 197–203. https://doi.org/10.1192/bjp.2018.247

Segal, Z. V., Williams, J. M. G., & Teasdale, J. D. (2002). Mindfulness-based cognitive therapy for depression: A new approach to preventing relapse. Guilford Press.

Strauss, C., Bibby-Jones, A.-M., Jones, F., Byford, S., Heslin, M., Parry, G., Barkham, M., Lea, L., Crane, R., de Visser, R., Arbon, A., Rosten, C., & Cavanagh, K. (2023). Clinical Effectiveness and Cost-Effectiveness of Supported Mindfulness-Based Cognitive Therapy Self-help Compared With Supported Cognitive Behavioral Therapy Self-help for Adults Experiencing Depression: The Low-Intensity Guided Help Through Mindfulness (LIGHTMind) Randomized Clinical Trial. JAMA Psychiatry, 80(5), 415–424. https://doi.org/10.1001/jamapsychiatry.2023.0222

Sverre, K. T., Nissen, E. R., Farver-Vestergaard, I., Johannsen, M., & Zachariae, R. (2023). Comparing the efficacy of mindfulness-based therapy and cognitive-behavioral therapy for depression in head-to-head randomized controlled trials: A systematic review and meta-analysis of equivalence. Clinical Psychology Review, 100, 102234. https://doi.org/10.1016/j.cpr.2022.102234

Swift, J. K., & Greenberg, R. P. (2012). Premature discontinuation in adult psychotherapy: A meta-analysis. Journal of Consulting and Clinical Psychology, 80(4), 547–559. https://doi.org/10.1037/a0028226

Williams, J. M. G., Crane, C., Barnhofer, T., Brennan, K., Duggan, D. S., Fennell, M. J. V., Hackmann, A., Krusche, A., Muse, K., Von Rohr, I. R., Shah, D., Crane, R. S., Eames, C., Jones, M., Radford, S., Silverton, S., Sun, Y., Weatherley-Jones, E., Whitaker, C. J., … Russell, I. T. (2014). Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: A randomized dismantling trial. Journal of Consulting and Clinical Psychology, 82(2), 275–286. https://doi.org/10.1037/a0035036

Zhou, Y., Zhao, D., Zhu, X., Liu, L., Meng, M., Shao, X., Zhu, X., Xiang, J., He, J., Zhao, Y., Yuan, Y., Gao, R., Jiang, L., & Zhu, G. (2023). Psychological interventions for the prevention of depression relapse: Systematic review and network meta-analysis. Translational Psychiatry, 13(1), 300. https://doi.org/10.1038/s41398-023-02604-1